Scarica l'app Stockscreener
0.00
0.22%
-9.14
Dopo l'orario di chiusura:
24.99
24.99
+
Flexion Therapeutics, Inc. Borsa (FLXN) Ultime notizie
Value vs Growth Ratio Hits Cycle Low—Top Value Picks to Buy - The Globe and Mail
Knee Osteoarthritis (OA) Injectable Treatments Market Revenue to Attain USD 5.94 Bn by 2033 - Precedence Research
Osteoarthritis Market is Predicted to Exhibit Remarkable Growth During the Forecast Period (2025-2034) | DelveInsight - The Malaysian Reserve
Syncromune Appoints Kerri-Ann Millar as Chief Financial Officer - citybiz
Syncromune® Appoints Industry Veteran Kerri-Ann Millar as Chief Financial Officer to Advance Corporate Growth Initiatives and Clinical Development Program - The Manila Times
Musculoskeletal Pain Therapeutics Market Size in 7MM - openPR.com
Catalyst Pharmaceuticals Announces Appointment of William T. Andrews, MD, FACP as Chief Medical Officer - GlobeNewswire
Catalyst Pharmaceuticals Appoints William T. Andrews, MD, FACP as Chief Medical Officer - citybiz
Catalyst Pharmaceuticals Taps Harvard-Yale Veteran with 18 Years Rare Disease Expertise as New CMO - Stock Titan
Catalyst Pharmaceuticals names new Chief Medical Officer By Investing.com - Investing.com India
Osteoarthritis Therapeutics Market Emerging Tech Trends to Watch from 2025 to 2032 - newstrail.com
Paratek Pharmaceuticals Completes Acquisition of Optinose, Creating an Expanded Portfolio of Specialty Therapies - The Manila Times
Marquis Who's Who Honors Shomari Hogan, MD, for Expertise in Consulting Services - 24-7 Press Release Newswire
Knee osteoarthritis Market: Epidemiology, Therapies, - openPR.com
Musculoskeletal Pain Treatment Market Size in 7MM is expected - openPR.com
Press Release Distribution & PR Platform - ACCESS Newswire
Osteoarthritis Therapeutics Market Size Unlocking New Opportunities for Success As Revealed In New Report - WhaTech
Anti-Inflammatory Therapeutics Market Recent - openPR.com
Dollar Gains on US Economic News and Hawkish Bostic - The Globe and Mail
Musculoskeletal Pain Therapeutics Market Size in 7MM is expected to grow at a decent CAGR by 2034, estimates DelveInsight - The Globe and Mail
Osteoarthritis Treatment Market 2034: EMA, PDMA, FDA Approval, - openPR.com
Osteoarthritis Treatment Market 2034: EMA, PDMA, FDA Approval, Clinical Trials, Epidemiology, Revenue, Statistics, Therapies, and Companies by DelveInsight - Barchart.com
USDCAD Completes A Correction Within An Uptrend - The Globe and Mail
Neogen (NEOG) To Report Earnings Tomorrow: Here Is What To Expect - The Globe and Mail
Nio Stock: The EV Darling That Still Can’t Deliver Profits - The Globe and Mail
Cautious Optimism for Building Products Distribution Rising as Sustained Demand for New Residential Construction Expected - The Globe and Mail
Knee Osteoarthritis Pipeline: Over 50 Innovators Pioneering Breakthrough Therapies | DelveInsight - openPR.com
Flexion Therapeutics Announces FDA Clearance of Investigational New Drug Application for FX301 - marketscreener.com
Flexion Therapeutics, Inc. Announces Executive Changes - MarketScreener
3 Reasons to Sell TNDM and 1 Stock to Buy Instead - The Globe and Mail
I'm Buying This Nvidia-Backed AI Company Before It Explodes - The Globe and Mail
Osteoarthritis Treatment Market Trends and Forecast 2034 - openPR.com
Rivian's Autonomy Push Is Another Potential Failure - The Globe and Mail
Flexion Therapeutics, Inc. to Host Earnings Call - ACCESS Newswire
Investor Network: Flexion Therapeutics, Inc. to Host Earnings Call - ACCESS Newswire
Pacira BioSciences Reports Fourth Quarter and Full-Year 2024 Financial Results - GlobeNewswire
Rocket Lab (RKLB) Q4 Earnings: What To Expect - The Globe and Mail
Q4 Earnings Roundup: Baxter (NYSE:BAX) And The Rest Of The Medical Devices & SuppliesDiversified Segment - The Globe and Mail
Armlogi Advances Supply Chain Solutions with Roadie, a UPS Company, Expanding Last-Mile Delivery Coverage to 97% of U.S. - The Globe and Mail
AMD Is Looking Like a No-Brainer Buy, Here's Why. - The Globe and Mail
Joint Pain Injections Market Set to Surge to $13.18 Billion by 2031 at a 7.7% CAGR - EIN News
3 Steel Stocks to Gain Strength as Tariffs Reshape the Market - The Globe and Mail
Week Ahead In Pharma (May 10- 14): FDA Decision, Data Readouts (RCKT, AVRO, FLXN, RARE, HRTX…) - RTTNews
CPRXCatalyst Pharmaceuticals Inc Latest Stock News & Market Updates - Stock Titan
Musculoskeletal Pain Therapeutics Market Size in the 7MM is expected to grow by 2034 and estimates DelveInsight - Barchart
Joint Pain Injections Market: Unleashing Growth Opportunities - openPR
[Expert View] Osteoarthritis Treatment Market Innovating Therapies for Joint Health Improvement | 20242033 - openPR
Osteoarthritis Therapeutics Market Size to Reach USD 24.34 Bn by 2034 - GlobeNewswire
iBio Strengthens Board with Appointment of Two New Independent Directors - GlobeNewswire
PCRX-201, a novel IL-1Ra gene therapy treatment approach for low back pain resulting from intervertebral disc degeneration - Nature
Osteoarthritis Therapeutics Market Size, Report By 2034 - Precedence Research
Gene Therapies For Rare Diseases Market Share, Size, Growth and Forecast to 2031 - InsightAce Analytic
Pacira Q3 Earnings Top, Revenues Miss Despite Exparel Sales Growth - Yahoo Finance
Pacira BioSciences Reports Third Quarter 2024 Financial Results - GlobeNewswire
Alkeus Pharmaceuticals Appoints David Arkowitz as Chief Financial Officer - GlobeNewswire
Global Anti-Aging Products Market is Projected to Cross ~USD 112 Billion by 2030 | DelveInsight - GlobeNewswire
Global Non-Steroidal Anti-Inflammatory Drugs Market is - GlobeNewswire
Avalo Therapeutics Welcomes Chief Medical Officer - Contract Pharma
Verily onboards Utpal Koppikar as CFO - World Business Outlook
Inogen names general counsel, and executive VP - Medical Buyer
Boston Pharmaceuticals Appoints Dr. Margaret Koziel as New Chief Medical Officer - Business Wire
Osteoarthritis Injectables Market Size & Share Report, 2030 - Grand View Research
U.S. Osteoarthritis Injectables Market | Industry Report, 2030 - Grand View Research
8.43%
1.68%
Capitalizzazione:
|
Volume (24 ore):